Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2- advanced breast cancer: a Brazilian public health care system perspective.

Daniela Dornelles RosaCarlos Alberto da Silva MaglianoSergio D SimonGilberto AmorimTomás ReinertLuciana LandeiroDébora de Melo GagliatoPedro ExmanDaniel ArgoloGisah GuilgenMax ManoLaura TestaPedro LiedkeRomualdo BarrosoMariana SasseAnna Maria Buehler

Published in: Therapeutic advances in medical oncology (2022)

Ribociclib increased PFLYs and QALYs in patients with HR+/HER2- ABC when added to ET. Because Brazil does not have a formally defined cost-effectiveness threshold, other domains need to be considered for incorporation decisions, such as disease burden and humanistic impact on this young, economically active population. These findings may be useful in discussions for incorporation of ribociclib into the Brazilian public health system.

Keyphrases

postmenopausal women
healthcare
mental health
breast cancer risk
risk factors
emergency department
drug induced